CBC Biomedical Undertook a Research and Development Project in 2016

CBC Biomedical undertook a research and development project in 2016.As of March 1 of that year,management concluded that the project had met the requirements for the capitalization of development costs.For the remainder of 2016 and 2017,the company capitalized $4.3 million of development costs for the project.Capitalizing these costs helped CBC Biomedical to remain profitable; had these costs been expensed,the company would report losses.In 2018,CBC Biomedical began amortizing the development cost over the estimated useful life of 10 years,beginning with a full year of amortization in 2018.
In 2021,in preparation for an initial public offering (IPO),the company engaged a public accounting firm to conduct an external audit of its financial statements.The auditors concluded that the development cost did not meet the criteria for capitalization.Specifically,it is their opinion that CBC Biomedical,at the time,did not demonstrate that the company had sufficient financial resources to complete the development project due to the recurring operating losses incurred.After some heated debate,CBC Biomedical management agreed with the auditors' position in order to obtain an unqualified audit opinion.The company had not yet recorded any amortization for 2021 when it agreed to correct the error.The company's tax rate is 30%.
Required:
Record the journal entries necessary to correct CBC's accounts.Include the effect of income taxes.

Correct Answer:

Verified

Adjusting entries to correct e...

View Answer

Unlock this answer now
Get Access to more Verified Answers free of charge

View Full Answer For Free